CR11510A - Uso de un inhibidor de la gamma-secretasa para tratamiento del cancer - Google Patents

Uso de un inhibidor de la gamma-secretasa para tratamiento del cancer

Info

Publication number
CR11510A
CR11510A CR11510A CR11510A CR11510A CR 11510 A CR11510 A CR 11510A CR 11510 A CR11510 A CR 11510A CR 11510 A CR11510 A CR 11510A CR 11510 A CR11510 A CR 11510A
Authority
CR
Costa Rica
Prior art keywords
gamma
cancer treatment
secretase inhibitor
patient
cancer
Prior art date
Application number
CR11510A
Other languages
English (en)
Inventor
John Frederick Boylan
Leopoldo Ladores Luistro Iii
Kathryn E Packman
Original Assignee
Hoffmann La Roche
Priority date (The priority date is an assumption and is not a legal conclusion. Google has not performed a legal analysis and makes no representation as to the accuracy of the date listed.)
Filing date
Publication date
Family has litigation
First worldwide family litigation filed litigation Critical https://patents.darts-ip.com/?family=40365425&utm_source=google_patent&utm_medium=platform_link&utm_campaign=public_patent_search&patent=CR11510(A) "Global patent litigation dataset” by Darts-ip is licensed under a Creative Commons Attribution 4.0 International License.
Application filed by Hoffmann La Roche filed Critical Hoffmann La Roche
Publication of CR11510A publication Critical patent/CR11510A/es

Links

Classifications

    • A—HUMAN NECESSITIES
    • A61—MEDICAL OR VETERINARY SCIENCE; HYGIENE
    • A61K—PREPARATIONS FOR MEDICAL, DENTAL OR TOILETRY PURPOSES
    • A61K31/00—Medicinal preparations containing organic active ingredients
    • A61K31/33—Heterocyclic compounds
    • A61K31/395—Heterocyclic compounds having nitrogen as a ring hetero atom, e.g. guanethidine or rifamycins
    • A61K31/55—Heterocyclic compounds having nitrogen as a ring hetero atom, e.g. guanethidine or rifamycins having seven-membered rings, e.g. azelastine, pentylenetetrazole
    • A—HUMAN NECESSITIES
    • A61—MEDICAL OR VETERINARY SCIENCE; HYGIENE
    • A61K—PREPARATIONS FOR MEDICAL, DENTAL OR TOILETRY PURPOSES
    • A61K31/00—Medicinal preparations containing organic active ingredients
    • A61K31/70—Carbohydrates; Sugars; Derivatives thereof
    • A61K31/7042—Compounds having saccharide radicals and heterocyclic rings
    • A61K31/7052—Compounds having saccharide radicals and heterocyclic rings having nitrogen as a ring hetero atom, e.g. nucleosides, nucleotides
    • A61K31/706—Compounds having saccharide radicals and heterocyclic rings having nitrogen as a ring hetero atom, e.g. nucleosides, nucleotides containing six-membered rings with nitrogen as a ring hetero atom
    • A61K31/7064—Compounds having saccharide radicals and heterocyclic rings having nitrogen as a ring hetero atom, e.g. nucleosides, nucleotides containing six-membered rings with nitrogen as a ring hetero atom containing condensed or non-condensed pyrimidines
    • A61K31/7068—Compounds having saccharide radicals and heterocyclic rings having nitrogen as a ring hetero atom, e.g. nucleosides, nucleotides containing six-membered rings with nitrogen as a ring hetero atom containing condensed or non-condensed pyrimidines having oxo groups directly attached to the pyrimidine ring, e.g. cytidine, cytidylic acid
    • A—HUMAN NECESSITIES
    • A61—MEDICAL OR VETERINARY SCIENCE; HYGIENE
    • A61P—SPECIFIC THERAPEUTIC ACTIVITY OF CHEMICAL COMPOUNDS OR MEDICINAL PREPARATIONS
    • A61P35/00—Antineoplastic agents
    • A—HUMAN NECESSITIES
    • A61—MEDICAL OR VETERINARY SCIENCE; HYGIENE
    • A61P—SPECIFIC THERAPEUTIC ACTIVITY OF CHEMICAL COMPOUNDS OR MEDICINAL PREPARATIONS
    • A61P35/00—Antineoplastic agents
    • A61P35/04—Antineoplastic agents specific for metastasis
    • A—HUMAN NECESSITIES
    • A61—MEDICAL OR VETERINARY SCIENCE; HYGIENE
    • A61P—SPECIFIC THERAPEUTIC ACTIVITY OF CHEMICAL COMPOUNDS OR MEDICINAL PREPARATIONS
    • A61P43/00—Drugs for specific purposes, not provided for in groups A61P1/00-A61P41/00

Landscapes

  • Health & Medical Sciences (AREA)
  • Life Sciences & Earth Sciences (AREA)
  • General Health & Medical Sciences (AREA)
  • Chemical & Material Sciences (AREA)
  • Veterinary Medicine (AREA)
  • Medicinal Chemistry (AREA)
  • Public Health (AREA)
  • Pharmacology & Pharmacy (AREA)
  • Animal Behavior & Ethology (AREA)
  • Epidemiology (AREA)
  • Nuclear Medicine, Radiotherapy & Molecular Imaging (AREA)
  • Organic Chemistry (AREA)
  • General Chemical & Material Sciences (AREA)
  • Chemical Kinetics & Catalysis (AREA)
  • Molecular Biology (AREA)
  • Engineering & Computer Science (AREA)
  • Bioinformatics & Cheminformatics (AREA)
  • Oncology (AREA)
  • Pharmaceuticals Containing Other Organic And Inorganic Compounds (AREA)
  • Medicines That Contain Protein Lipid Enzymes And Other Medicines (AREA)

Abstract

La presente invencion proporciona un metodo para tratar a un paciente que tenga cancer que consiste en administrar al paciente una cantidad terapeuticamente eficaz del compuesto (I), o una sal farmaceuticamente aceptable del mismo que tiene la formula.
CR11510A 2008-01-11 2010-06-17 Uso de un inhibidor de la gamma-secretasa para tratamiento del cancer CR11510A (es)

Applications Claiming Priority (1)

Application Number Priority Date Filing Date Title
US2044708P 2008-01-11 2008-01-11

Publications (1)

Publication Number Publication Date
CR11510A true CR11510A (es) 2010-09-13

Family

ID=40365425

Family Applications (1)

Application Number Title Priority Date Filing Date
CR11510A CR11510A (es) 2008-01-11 2010-06-17 Uso de un inhibidor de la gamma-secretasa para tratamiento del cancer

Country Status (17)

Country Link
US (1) US20090181944A1 (es)
EP (1) EP2244713A1 (es)
JP (3) JP5612482B2 (es)
KR (2) KR20100101624A (es)
CN (1) CN101909633B (es)
AR (1) AR072442A1 (es)
AU (1) AU2009203776A1 (es)
BR (1) BRPI0906831A2 (es)
CA (1) CA2710913A1 (es)
CL (1) CL2009000040A1 (es)
CR (1) CR11510A (es)
IL (1) IL206361A0 (es)
MA (1) MA33076B1 (es)
RU (1) RU2010133489A (es)
TW (1) TW200936139A (es)
WO (1) WO2009087130A1 (es)
ZA (1) ZA201004859B (es)

Families Citing this family (31)

* Cited by examiner, † Cited by third party
Publication number Priority date Publication date Assignee Title
EP2094836B1 (en) 2006-11-15 2016-06-08 Massachusetts Eye & Ear Infirmary Generation of inner ear cells
JP5809061B2 (ja) 2008-11-24 2015-11-10 マサチューセッツ・アイ・アンド・イア・インファーマリー 有毛細胞を産生するための経路
US8309299B2 (en) * 2010-05-19 2012-11-13 Hoffmann-La Roche Inc. Combination therapy and method for assessing resistance to treatment
WO2012050370A2 (ko) * 2010-10-15 2012-04-19 성균관대학교산학협력단 감마-세크레타제 저해제를 유효성분으로 함유하는 류마티스성 관절염의 예방 또는 치료용 조성물
KR101330184B1 (ko) 2010-10-15 2013-11-15 성균관대학교산학협력단 감마-세크레타제 저해제를 유효성분으로 함유하는 류마티스성 관절염의 예방 또는 치료용 조성물
US20120114638A1 (en) * 2010-11-08 2012-05-10 John Boylan Combination therapy
US20120225860A1 (en) * 2011-03-02 2012-09-06 John Frederick Boylan Method for administration of a gamma secretase inhibitor
TWI530489B (zh) 2011-03-22 2016-04-21 必治妥美雅史谷比公司 雙（氟烷基）－１，４－苯二氮呯酮化合物
JO3148B1 (ar) 2011-07-27 2017-09-20 Lilly Co Eli مركب مثبط لإشارات مسار notch
JP2015527398A (ja) 2012-09-07 2015-09-17 マサチューセッツ アイ アンド イヤー インファーマリー 聴覚喪失治療
EP2897942B1 (en) 2012-09-21 2016-08-31 Bristol-Myers Squibb Company Fluoroalkyl and fluorocycloalkyl 1,4-benzodiazepinone compounds as notch inhibitors
EP2897944B1 (en) 2012-09-21 2016-10-26 Bristol-Myers Squibb Company Substituted 1,5-benzodiazepinone compounds
JP2015533811A (ja) 2012-09-21 2015-11-26 ブリストル−マイヤーズ スクイブ カンパニーＢｒｉｓｔｏｌ−Ｍｙｅｒｓ Ｓｑｕｉｂｂ Ｃｏｍｐａｎｙ Ｎ−置換ビス（フルオロアルキル）１，４−ベンゾジアゼピノン化合物
EP2897960B1 (en) 2012-09-21 2016-08-03 Bristol-Myers Squibb Company Tricyclic heterocyclic compounds as notch inhibitors
TWI614238B (zh) 2012-09-21 2018-02-11 必治妥美雅史谷比公司 雙（氟烷基）－１，４－苯并二氮呯酮化合物及其前藥
EP2897938B1 (en) 2012-09-21 2017-03-15 Bristol-Myers Squibb Company Fluoroalkyl dibenzodiazepinone compounds
JP2015534554A (ja) 2012-09-21 2015-12-03 ブリストル−マイヤーズ スクイブ カンパニーＢｒｉｓｔｏｌ−Ｍｙｅｒｓ Ｓｑｕｉｂｂ Ｃｏｍｐａｎｙ アルキル，フルオロアルキル−１，４−ベンゾジアゼピノン化合物
US9273075B2 (en) 2012-09-21 2016-03-01 Bristol-Myers Squibb Company Prodrugs of 1,4-benzodiazepinone compounds
CN104822677A (zh) 2012-09-21 2015-08-05 百时美施贵宝公司 氟烷基-1,4-苯并二氮杂*酮化合物
EP2981267A1 (en) * 2013-04-04 2016-02-10 Bristol-Myers Squibb Company Combination therapy for the treatment of proliferative diseases
CA2934250A1 (en) * 2013-12-17 2015-06-25 Rush University Medical Center Compositions and methods for treating diabetic nephropathy
WO2016022776A2 (en) 2014-08-06 2016-02-11 Massachusetts Eye And Ear Infirmary Increasing atoh1 life to drive sensorineural hair cell differentiantion
US11370823B2 (en) 2014-10-29 2022-06-28 Massachusetts Eye And Ear Infirmary Efficient delivery of therapeutic molecules to cells of the inner ear
WO2017096233A1 (en) 2015-12-04 2017-06-08 Massachusetts Eye And Ear Infirmary Treatment of hearing loss by inhibition of casein kinase 1
CA3013038A1 (en) 2016-01-29 2017-08-03 Massachusetts Eye And Ear Infirmary Expansion and differentiation of inner ear supporting cells and methods of use thereof
ES2898952T3 (es) 2016-04-12 2022-03-09 Lilly Co Eli Terapia de combinación con inhibidores de Notch y PI3K/mTOR para su uso en el tratamiento del cáncer de ovario
AU2017268078B2 (en) 2016-05-16 2023-03-02 The General Hospital Corporation Human airway stem cells in lung epithelial engineering
SG11201810268YA (en) 2016-05-20 2018-12-28 Lilly Co Eli Combination therapy with notch and pd-1 or pd-l1 inhibitors
IL267253B2 (en) 2016-12-16 2023-04-01 Pipeline Therapeutics Inc Methods for treating cochlear synaptopathy
KR102094442B1 (ko) 2018-06-28 2020-03-27 성균관대학교산학협력단 알쯔하이머성 치매의 예방 또는 치료용 물질 및 이를 포함하는 조성물
WO2022067185A1 (en) * 2020-09-27 2022-03-31 Veru Inc. Methods of treating prostate cancer with minimal side effects

Family Cites Families (6)

* Cited by examiner, † Cited by third party
Publication number Priority date Publication date Assignee Title
US6012A (en) * 1849-01-09 Lithographing co
EP1711470B1 (en) * 2003-09-09 2009-04-15 F. Hoffmann-La Roche Ag Malonamide derivatives blocking the activtiy of gamma-secretase
US7211573B2 (en) * 2004-12-08 2007-05-01 Hoffmann-La Roche Inc. Malonamide derivatives
CA2597933A1 (en) * 2005-02-15 2006-08-24 Novartis Vaccines And Diagnostics, Inc. Methods for treating lymphomas using a combination of a chemotherapeutic agent and il-2 and optionally an anti-cd20 antibody
EP1888051A2 (en) * 2005-05-17 2008-02-20 MERCK SHARP & DOHME LTD. Sulphonamido-substituted cyclohexyl sulphones for treatment of cancer
EP2198863A1 (en) * 2006-02-27 2010-06-23 The Johns Hopkins University Cancer treatment with gamma-secretase inhibitors

Also Published As

Publication number Publication date
US20090181944A1 (en) 2009-07-16
BRPI0906831A2 (pt) 2019-09-24
CL2009000040A1 (es) 2010-02-12
RU2010133489A (ru) 2012-02-20
JP2011509273A (ja) 2011-03-24
JP5612482B2 (ja) 2014-10-22
JP2014221772A (ja) 2014-11-27
TW200936139A (en) 2009-09-01
IL206361A0 (en) 2010-12-30
CA2710913A1 (en) 2009-07-16
CN101909633A (zh) 2010-12-08
MA33076B1 (fr) 2012-03-01
ZA201004859B (en) 2011-03-30
KR20100101624A (ko) 2010-09-17
AR072442A1 (es) 2010-09-01
AU2009203776A1 (en) 2009-07-16
EP2244713A1 (en) 2010-11-03
KR20140007979A (ko) 2014-01-20
CN101909633B (zh) 2012-05-30
WO2009087130A1 (en) 2009-07-16
JP2013241443A (ja) 2013-12-05

Similar Documents

Publication Publication Date Title
CR11510A (es) Uso de un inhibidor de la gamma-secretasa para tratamiento del cancer
UY32062A (es) Inhibidores de beta-secretasa
NI200900184A (es) Uso de compuestos inhibidores de quinaxolina de pi3k-alfa para el tratamiento del cáncer.
EA201692506A2 (ru) Ингибиторы репликации вирусов гриппа
EA200970932A1 (ru) Способы лечения с применением пиридопиримидиноновых ингибиторов pi3k альфа
BR112012009376A2 (pt) composição farmacêutica, forma de dosagem farmacêutica, processo para a sua preparação, métodos de tratamento e seu uso
GT201100181A (es) "inhibidores de proteina cinasa"
UY33480A (es) Compuestos terapeuticos, composicion farmaceutica que lo comprende, metodo de tratamiento y su uso para la manufactura de un medicamento.
PA8850801A1 (es) Compuestos útiles para inhibir chk1
EA201270570A1 (ru) Комбинированная терапия раковых заболеваний с помощью соединений-ингибиторов hsp90
AR077629A1 (es) Mimetico de smac
CO2020013600A2 (es) Tratamiento de la hidradenitis supurativa mediante el uso de inhibidores de jak
ECSP099436A (es) Acilaminopirazoles como inhibidores de fgfr
AR101740A1 (es) Terapia de combinación y composiciones
CR20120177A (es) Nuevos compuestos de espiropiperidina y el uso farmacéutico del mismo para el tratamiento de diabetes
MX2016015434A (es) Combinaciones farmaceuticas para tratar cancer.
CR11418A (es) Trans-clomifeno para el sindrome metabolico
CR9721A (es) Compuestos de carbamato para utilizar en el tratamiento de desordenes neurodegenerativos
UY30158A1 (es) Uso de derivados de benzo-heteroaril sulfamida para el tratamiento del dolor
GT200600160A (es) Tratamiento del dolor
BRPI0906444B8 (pt) compostos de 4-piridinona, composição farmacêutica que os compreende, bem como uso dos mesmos
UY33221A (es) MÉTODOS PARA TRATAR CÁNCER USANDO INHIBIDORES DE PI3K Y mTOR EN COMBINACIÓN CON INHIBIDORES DE AUTOFAGIA
AR093182A1 (es) Metodo para tratar el sobrepeso o la obesidad
AR084216A1 (es) Composiciones y metodos para tratar el cancer usando un inhibidor de pi3k e inhibidor de mek, kit
CL2007003251A1 (es) Compuestos derivados de 1h-pirazoles sustituidos, inhibidores de reacciones catalizadas por una quinasa; su procedimiento de preparacion; composicion farmaceutica; compuestos intermediarios; uso de los compuestos principales, utiles en el tratamiento del cancer.

Legal Events

Date Code Title Description
FA Abandonment or withdrawal (granting procedure)